Tibolon – the only one member of STEAR’s group

Landgren MB, Coelingh Bennink HJT, Helmond FA et al. Dose response analysis of effect of tibolone on climacteric symptoms. Br J Obstet Gynaecol 2002; 109: 1109–1114.

Hammar M, Christau S, Nathorst-Boos J et al. A double blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904–911.

Huber J, Palacios S, Berglund L et al. The effect of tibolone compared with CEE continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life and tolerability in postmenopausal women, Br J Obstet Gynaecol 2002; 109: 886–893.

Mendoza N, Pison JA, Fernandez M et al. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002; 41: 289–298.

Baracat EC, Barbosa IC, Giordano MG et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone. Climacteric 2002; 5: 60–69.

Davis SR. The effect of tibolone on mood and libido. Menopause 2002; 9: 162–170.

Tax L, Goorissen EM, Kucovic PM. Clinical profile Org OD14. Maturitas 1987 (Suppl 1): 3–13.

Lindsay PC, Shaw RW, Coeling Benning HJ et al. The effect of add back treatment with tibolone on patients treated with the GnRH agonist triptorelin. Fertil Steril 1996; 65: 342–348.

Palomba S, Affinito P, Di Carlo C et al. Long-term administration of tibolone plus GnRH agonist for the treatment of uterine leiomyomas. Fertil Steril 1999; 72: 889–895.

Egarter C, Sator M, Berghammer P et al. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. Int J Gynecol Obstet 1999; 64: 281–286.

Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. Maturitas 2005; 51: 21–28.

Meeuwsen IB, Samson MM, Duursma SA et al. The influence of tibolone on quality of life in postmenopausal women. Maturitas 2002; 41: 35–43.

Fait T, Žižka Z. Mammographic density – a risk factor for breast cancer. Prague Medical Report 2007; 108: 205–214.

Valdivia I, Campodónico I, Capia A et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004; 81: 617–623.

Lundström E, Christow A, Kersemaekers W et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. AJOG 2002; 186: 717–722.

Bruce D, Robinson J, McWilliams S et al. Long‑term effects of tibolone on mammographic density. Fertil Steril 2004; 82: 1343–1347.

Yenen MC, Dede M, Goktolga U et al. Hormone replacement therapy in postmenopausal women with benign fibrocystic mastopathy. Climacteric 2003; 6: 146–150.

Hammar M, Christau S, Nathorst-Boos J et al. A double blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms BJOG 1998; 105: 904–911.

Huber J, Palacios S, Berglund L et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 2002; 109: 886–893.

Speroff L. The Million Women Study and breast cancer. Maturitas 2003; 46: 1–6.

Nijland EA, Nathorst-Boos J, Palacios S et al. Improved bleeding profile and tolerability of tibolone versus transdermal E₂/NETA treatment in postmenopausal women with female sexual disfunction. Climacteric 2009; 12: 114–121.

Nijland EA, Weijmar Schultz WC, Nathorst-Boos J et al. Tibolone and E₂/NETA for the treatment of female sexual dysfunction in naturally menopausal women. J Sex Med 2008; 5: 646–656.

Delmas PD, Davis SR, Hensen J et al. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int 2008; 19: 1153–1160.

Cummings SR, Ettinger B, Delmas PD et al. The effect of tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697–708.

Kenemans P, Bundred NJ, Foidart JM et al. Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind randomised, non-inferiority trial. Lancet Oncol 2009; 10: 135–146.

Archer DF, Hendrix S, Ferenczy A et al. Tibolone histology of the endometrium and breast endpoints study. Fertil Steril 2007; 88: 866–878.

Archer DF, Hendrix S, Gallagher JC et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007; 92: 911–918.

Hammar ML, van de Weijer P, Franke HR et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 2007; 114: 1522–1529.

Bots ML, Evans GW, Riley W et al. The effect of tibolone and continuous combined CEE plus MPA on progression of CIM thickness. Eur Heart J 2006; 27: 746–755.

Langer RD, Landgren BM, Rymer J, Helmond FA. Effects of tibolone and continuous CEE/MPA on the endometrium and vaginal bleeding. AJOG 2006; 195: 1320–1327.